Home/ Supplements/ Vitamin K/ Omega-3 2100 with Vitamin K2 & D3 Natura...

Omega-3 2100 with Vitamin K2 & D3 Natural Orange Flavor

product on market Softgel Capsule Oceanblue Professional Safety: 100/100
100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 43% of ingredients have research evidence
A Label Compliance Grade

What the Evidence Says

AI-generated · Qwen 3.6 · methodology

Vitamin D is supported by strong evidence for maintaining bone health and immune function. Omega-3 fatty acids are widely researched for supporting cardiovascular health and reducing inflammation. The overall evidence coverage for this specific formulation is limited.

AI-generated summary based on research evidence. Not medical advice.

Label

Product Label

Label for Omega-3 2100 with Vitamin K2 & D3 Natural Orange Flavor
Open Full PDF View on NIH DSLD →
Details

Label Data

2 Softgel(s)
Serving Size
30
Servings
Other Combinations
Product Type
43%
Evidence Coverage
Ingredients

Supplement Facts — Evidence Check

Calories
30 Calorie(s)
Total Fat
3 Gram(s) (2% DV)
Cholesterol
15 mg (5% DV)
Protein
1 Gram(s)
50 mcg (250% DV)
3.3× RDA — above typical dose (UL: 0.1 mg) 608 studies (A:16, B:251)
Market median: 750.0mg (447 products) 393 studies (A:18, B:204)
100 mcg
Within RDA (0.8× RDA) 275 studies (A:9, B:175)

Other Ingredients

highly refined and concentrated Omega-3 Fish Oil Gelatin Glycerin Water, Purified D-Limonene Cholecalciferol Vitamin K2 Mixed Tocopherols, Natural
Claims

Label Claims — Verification

Unverified Nutrient
Unverified All Other
Unverified Qualified Health
Unverified Structure/Function
Info

Product Information

Directions for Use

Suggested use: take 2 softgels daily with meal.

Warnings & Precautions

Allergen warning: Contains fish and soy derivatives.

Keep out of reach of children.

Do not use if safety seal is damaged or missing.

Formulation Notes

Omega 2100 mg + K2 & D3 provides a combination of ingredients to support heart and bone health. Vitamin D3 supports your body absorb calcium; and the vitamin K2 transports calcium from the bloodstream into the bone, supporting bone density and cardiovascular health.

Traceability of our Omega-3 oils back to their source.

Purity of our products to safeguard the health of your family. Third party tested

No detectable mercury

Supportive but not conclusive research shows that consumption of EPA and DHA Omega-3 fatty acids may reduce the risk of coronary heart disease.

High-potency Joint & heart support

2,100mg omega-3 1350 mg EPA 600 mg DHA 150 mg DPA + 100 mcg K2 + 2000 IU D3

Additional Information

Ocean blue promise Transparency in our formulations and our labeling. Trust in our stewardship of the Seas.

Manufactured in the USA

(30 day supply)

Friend of the Sea

Great tasting No burps

Store in a cool dry place.

Metadata

Product Details

UPC / SKU8 50001 44933 5
DSLD Entry Date2023-09-25
Product TypeOther Combinations
FormSoftgel Capsule
DSLD ID293784
Data Updated2026-04-11
Research

Research Evidence

332
Research Sources
59
Avg Quality
220
Meta Analysis
56
Systematic Review
30
Rct
16
Clinical Trial
3
Guideline
3
Regulatory Source
1
Narrative Review
1
Other
1
Openfda Safety
A Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
Meta Analysis The Cochrane database of systematic reviews 2014 PubMed DOI
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2017 PubMed DOI
A Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2016 PubMed DOI
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2020 PubMed DOI
A Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2025 PubMed DOI
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2018 PubMed DOI
A Antiplatelet agents and anticoagulants for hypertension
Systematic Review The Cochrane database of systematic reviews 2022 PubMed DOI
A Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Meta Analysis The Cochrane database of systematic reviews 2012 PubMed DOI
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2013 PubMed DOI
A Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Meta Analysis The Cochrane database of systematic reviews 2014 PubMed DOI
View all evidence for Vitamin K →
Compare

Similar Products

View all Vitamin K products →

This product page is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before taking any supplement.